Effects of thiazolidinedione and biguanide in groups divided according to diabetic pathophysiology

Effects of thiazolidinedione and biguanide in groups divided according to diabetic pathophysiology - Effects of thiazolidinedione and biguanide in groups divided according to diabetic pathophysiology

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005266

Enrollment

Registered

2011-03-22

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

thiazolidinedione biguanide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who had been admitted to Osaka University Hospital and were treated by diet alone or diet plus insulin for at least 2 weeks, until fasting plasma glucose (FPG) was below 7.0 mmol/l, and then insulin resistance was evaluated by the insulin tolerance test and HOMA-IR

Exclusion criteria

Exclusion criteria: 1. heart failure 2. severe liver and/or renal dysfunction 3. heavy drinkers, infectious disease, around operation, pregnancy patients whom the doctor regarded as imapropriate for the subjects

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Contacts

Public ContactJunji Kozawa

Graduate School of Medicine, Osaka University Metabolic Medicine

kjunji@imed2.med.Osaka-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026